Corbus Pharmaceuticals Holdings, Inc. (CRBP): Yuval Cohen , CEO of Corbus Pharmaceuticals Holdings, Inc. purchased 1,500 shares on Jun 6, 2016. The Insider buying transaction was reported by the company on Jun 7, 2016 to the Securities and Exchange Commission. The shares were purchased at $3.34 per share for a total value of $5,010.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 2, 2016, Barbara White (Chief Medical Officer) purchased 2,570 shares at $3.52 per share price.On May 19, 2016, Sean F. Moran (CFO) purchased 27,250 shares at $2.37 per share price.Also, On May 19, 2016, Yuval Cohen (CEO) purchased 2,125 shares at $2.40 per share price.On Aug 21, 2015, Sumner Burstein (10% owner) sold 200,000 shares at $3.04 per share price.
Shares of Corbus Pharmaceuticals Holdings Inc (CRBP) ended Friday, Jun 3, 2016 session in red amid volatile trading. The shares closed down -0.03 points or -0.79% at $3.75 with 4,14,227 shares getting traded. Post opening the session at $3.75, the shares hit an intraday low of $3.55 and an intraday high of $3.85 and the price vacillated in this range throughout the day. The company has a market cap of $141 M and the number of outstanding shares has been calculated to be 3,76,06,165 shares. The 52-week high of Corbus Pharmaceuticals Holdings Inc is $4.22 and the 52-week low is $1.01.
Corbus Pharmaceuticals Holdings Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare life-threating inflammatory-fibrotic diseases. The Company’s lead product candidate Resunab is an oral anti-inflammatory drug that is being developed for the treatment of inflammatory disorders such as cystic fibrosis (CF) and scleroderma. The Company has completed the Phase I safety studies for the treatment of scleroderma and cystic fibrosis. The Company has submitted an Investigational New Drug Application (INDA) to the United States Food and Drug Administration (FDA) for a Phase IIa double-blind placebo controlled clinical study evaluating Resunab in patients with diffuse scleroderma. Pre-clinical and Phase I clinical studies (123 subjects) have shown Resunab to have a favorable safety profile coupled with suitable potency in pre-clinical models of inflammation and fibrosis.